erlotinib hydrochloride has been researched along with saracatinib in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (saracatinib) | Trials (saracatinib) | Recent Studies (post-2010) (saracatinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 194 | 25 | 157 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | saracatinib (IC50) |
|---|---|---|---|
| Chain A, Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.03 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 1.9615 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.004 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0038 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.2 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.0093 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 10 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 10 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 0.84 | |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | 5.209 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
1 review(s) available for erlotinib hydrochloride and saracatinib
| Article | Year |
|---|---|
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
1 other study(ies) available for erlotinib hydrochloride and saracatinib
| Article | Year |
|---|---|
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |